Anti-Human CD41/CD61 Reference Antibody (Tadocizumab, RUO)

Description: Tadocizumab (BS10129) is a research-grade recombinant antibody targeting CD41. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: Fab-G1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD41,ITGAB,GPIIb,ITGA2B,PlateletmembraneglycoproteinIIb,GP2B,Integrinalpha-IIb,GPalphaIIb,GPIIIa,Integrinbeta-3,CD61,ITGB3,PlateletmembraneglycoproteinIIIa,GP3A
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: C4G1,YM-337,CAS:339086-80-5
Background: Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
Note: For research use only. Not suitable for clinical or therapeutic use.